(Q37728598)

22 August 2017

1 reference

title

Tuberculosis drug development: progress, challenges, and the road ahead (English)

1 reference

22 August 2017

0 references

Ann M Ginsberg

1

1 reference

22 August 2017

publication date

9 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

90

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

162-167

1 reference

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Linezolid: a review of safety and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Linezolid in the treatment of multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Advances in immunotherapy for tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

STREPTOMYCIN treatment of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Gatifloxacin and dysglycemia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Outpatient gatifloxacin therapy and dysglycemia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.003

10.1016/J.TUBE.2010.03.003

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference